Wuhan Healthgen Biotechnology Corp. (SHA:688765)

Market Cap	14.24B
Revenue (ttm)	23.39M -3.6%
Net Income	-160.81M
EPS	-0.59
Shares Out	357.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,350,272
Open	39.48
Previous Close	39.47
Day's Range	39.33 - 40.86
52-Week Range	32.61 - 132.03
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 23, 2026

About SHA:688765

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial growth factor, recombinant human keratinocyte growth factor, recombinant human...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 215
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688765

Financial Performance

In 2024, SHA:688765's revenue was 25.22 million, an increase of 3.92% compared to the previous year's 24.26 million. Losses were -151.37 million, -19.04% less than in 2023.

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Oct 8, 2026

Data Sources Report a data error